Open Access
Open access
Antibiotics, volume 9, issue 1, pages 17

More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin

Gray Declan Alan 1
Wenzel Michaela 2
Publication typeJournal Article
Publication date2020-01-03
Journal: Antibiotics
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor4.8
ISSN20796382
Biochemistry
Microbiology (medical)
Microbiology
Infectious Diseases
Pharmacology (medical)
General Pharmacology, Toxicology and Pharmaceutics
Abstract

Daptomycin is a cyclic lipopeptide antibiotic, which was discovered in 1987 and entered the market in 2003. To date, it serves as last resort antibiotic to treat complicated skin infections, bacteremia, and right-sided endocarditis caused by Gram-positive pathogens, most prominently methicillin-resistant Staphylococcus aureus. Daptomycin was the last representative of a novel antibiotic class that was introduced to the clinic. It is also one of the few membrane-active compounds that can be applied systemically. While membrane-active antibiotics have long been limited to topical applications and were generally excluded from systemic drug development, they promise slower resistance development than many classical drugs that target single proteins. The success of daptomycin together with the emergence of more and more multi-resistant superbugs attracted renewed interest in this compound class. Studying daptomycin as a pioneering systemic membrane-active compound might help to pave the way for future membrane-targeting antibiotics. However, more than 30 years after its discovery, the exact mechanism of action of daptomycin is still debated. In particular, there is a prominent discrepancy between in vivo and in vitro studies. In this review, we discuss the current knowledge on the mechanism of daptomycin against Gram-positive bacteria and try to offer explanations for these conflicting observations.

Citations by journals

1
2
3
4
5
ACS Infectious Diseases
ACS Infectious Diseases, 5, 7.81%
ACS Infectious Diseases
5 publications, 7.81%
Pharmaceutics
Pharmaceutics, 3, 4.69%
Pharmaceutics
3 publications, 4.69%
Antibiotics
Antibiotics, 3, 4.69%
Antibiotics
3 publications, 4.69%
Microbiology spectrum
Microbiology spectrum, 3, 4.69%
Microbiology spectrum
3 publications, 4.69%
Angewandte Chemie - International Edition
Angewandte Chemie - International Edition, 2, 3.13%
Angewandte Chemie - International Edition
2 publications, 3.13%
Microbiology
Microbiology, 2, 3.13%
Microbiology
2 publications, 3.13%
Frontiers in Microbiology
Frontiers in Microbiology, 2, 3.13%
Frontiers in Microbiology
2 publications, 3.13%
Angewandte Chemie
Angewandte Chemie, 2, 3.13%
Angewandte Chemie
2 publications, 3.13%
Organic and Biomolecular Chemistry
Organic and Biomolecular Chemistry, 2, 3.13%
Organic and Biomolecular Chemistry
2 publications, 3.13%
Advanced Science
Advanced Science, 1, 1.56%
Advanced Science
1 publication, 1.56%
mBio
mBio, 1, 1.56%
mBio
1 publication, 1.56%
Analytical Chemistry
Analytical Chemistry, 1, 1.56%
Analytical Chemistry
1 publication, 1.56%
Biomolecules
Biomolecules, 1, 1.56%
Biomolecules
1 publication, 1.56%
Microorganisms
Microorganisms, 1, 1.56%
Microorganisms
1 publication, 1.56%
Polymers
Polymers, 1, 1.56%
Polymers
1 publication, 1.56%
Membranes
Membranes, 1, 1.56%
Membranes
1 publication, 1.56%
Frontiers in Cellular and Infection Microbiology
Frontiers in Cellular and Infection Microbiology, 1, 1.56%
Frontiers in Cellular and Infection Microbiology
1 publication, 1.56%
Frontiers in Bioengineering and Biotechnology
Frontiers in Bioengineering and Biotechnology, 1, 1.56%
Frontiers in Bioengineering and Biotechnology
1 publication, 1.56%
Frontiers in Immunology
Frontiers in Immunology, 1, 1.56%
Frontiers in Immunology
1 publication, 1.56%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 1, 1.56%
International Journal of Molecular Sciences
1 publication, 1.56%
Scientific Reports
Scientific Reports, 1, 1.56%
Scientific Reports
1 publication, 1.56%
Amino Acids
Amino Acids, 1, 1.56%
Amino Acids
1 publication, 1.56%
Journal of Emergency Medicine
Journal of Emergency Medicine, 1, 1.56%
Journal of Emergency Medicine
1 publication, 1.56%
Applied Microbiology and Biotechnology
Applied Microbiology and Biotechnology, 1, 1.56%
Applied Microbiology and Biotechnology
1 publication, 1.56%
Nature Communications
Nature Communications, 1, 1.56%
Nature Communications
1 publication, 1.56%
Asian Journal of Pharmaceutical Sciences, 1, 1.56%
Asian Journal of Pharmaceutical Sciences
1 publication, 1.56%
PLoS Pathogens
PLoS Pathogens, 1, 1.56%
PLoS Pathogens
1 publication, 1.56%
Microbiology and Molecular Biology Reviews
Microbiology and Molecular Biology Reviews, 1, 1.56%
Microbiology and Molecular Biology Reviews
1 publication, 1.56%
Journal of Peptide Science
Journal of Peptide Science, 1, 1.56%
Journal of Peptide Science
1 publication, 1.56%
1
2
3
4
5

Citations by publishers

2
4
6
8
10
12
14
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 13, 20.31%
Multidisciplinary Digital Publishing Institute (MDPI)
13 publications, 20.31%
American Society for Microbiology
American Society for Microbiology, 8, 12.5%
American Society for Microbiology
8 publications, 12.5%
Wiley
Wiley, 7, 10.94%
Wiley
7 publications, 10.94%
American Chemical Society (ACS)
American Chemical Society (ACS), 7, 10.94%
American Chemical Society (ACS)
7 publications, 10.94%
Frontiers Media S.A.
Frontiers Media S.A., 6, 9.38%
Frontiers Media S.A.
6 publications, 9.38%
Springer Nature
Springer Nature, 5, 7.81%
Springer Nature
5 publications, 7.81%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 3, 4.69%
Royal Society of Chemistry (RSC)
3 publications, 4.69%
Microbiology Society
Microbiology Society, 2, 3.13%
Microbiology Society
2 publications, 3.13%
Elsevier
Elsevier, 1, 1.56%
Elsevier
1 publication, 1.56%
Shenyang Pharmaceutical University, 1, 1.56%
Shenyang Pharmaceutical University
1 publication, 1.56%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 1, 1.56%
Public Library of Science (PLoS)
1 publication, 1.56%
eLife Sciences Publications
eLife Sciences Publications, 1, 1.56%
eLife Sciences Publications
1 publication, 1.56%
Cold Spring Harbor Laboratory
Cold Spring Harbor Laboratory, 1, 1.56%
Cold Spring Harbor Laboratory
1 publication, 1.56%
2
4
6
8
10
12
14
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Gray D. A., Wenzel M. More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin // Antibiotics. 2020. Vol. 9. No. 1. p. 17.
GOST all authors (up to 50) Copy
Gray D. A., Wenzel M. More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin // Antibiotics. 2020. Vol. 9. No. 1. p. 17.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3390/antibiotics9010017
UR - https://doi.org/10.3390%2Fantibiotics9010017
TI - More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin
T2 - Antibiotics
AU - Gray, Declan Alan
AU - Wenzel, Michaela
PY - 2020
DA - 2020/01/03 00:00:00
PB - Multidisciplinary Digital Publishing Institute (MDPI)
SP - 17
IS - 1
VL - 9
PMID - 31947747
SN - 2079-6382
ER -
BibTex |
Cite this
BibTex Copy
@article{2020_Gray,
author = {Declan Alan Gray and Michaela Wenzel},
title = {More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin},
journal = {Antibiotics},
year = {2020},
volume = {9},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
month = {jan},
url = {https://doi.org/10.3390%2Fantibiotics9010017},
number = {1},
pages = {17},
doi = {10.3390/antibiotics9010017}
}
MLA
Cite this
MLA Copy
Gray, Declan Alan, and Michaela Wenzel. “More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin.” Antibiotics, vol. 9, no. 1, Jan. 2020, p. 17. https://doi.org/10.3390%2Fantibiotics9010017.
Found error?